Parker Jewish Institute Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2010
NCT01202630
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Alternative names

Parker Jewish for Health Care and Rehabilitation

Active Ingredients

Drugs in Phase 3 Trials (2)

Lactobacillus acidophilus (1 trial)

lactobacillus casei (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Clostridium Infections (Phase 3)

Communicable Diseases (Phase 3)

Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2